Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ABP NASDAQ:GTBP NASDAQ:LSB NASDAQ:MURA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeABPAbpro$0.22-2.3%$0.22$0.15▼$13.00$13.50MN/A6.42 million shs9.12 million shsGTBPGT Biopharma$1.99-1.5%$2.69$1.72▼$4.10$6.51M1.48249,467 shs38,562 shsLSBLakeShore Biopharma$1.19+10.2%$1.05$0.87▼$8.60$9.68M0.5889,882 shs126,557 shsMURAMural Oncology$2.45-1.2%$2.57$0.95▼$4.74$42.31M3.031.28 million shs125,435 shs7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceABPAbpro+11.43%+14.81%+8.86%-14.91%+22,719,900.00%GTBPGT Biopharma-1.94%-5.61%-33.77%-6.48%-26.55%LSBLakeShore Biopharma+3.84%-2.70%+10.20%-20.30%-77.95%MURAMural Oncology-0.80%-2.36%+1.22%-8.82%-27.70%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationABPAbproN/AN/AN/AN/AN/AN/AN/AN/AGTBPGT Biopharma1.4002 of 5 stars3.81.00.00.00.60.00.6LSBLakeShore Biopharma0.3631 of 5 stars0.03.00.00.00.60.80.6MURAMural Oncology3.3701 of 5 stars3.35.00.00.02.21.71.3Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceABPAbpro 3.00Buy$4.001,701.80% UpsideGTBPGT Biopharma 3.50Strong Buy$11.00452.76% UpsideLSBLakeShore Biopharma 0.00N/AN/AN/AMURAMural Oncology 2.50Moderate Buy$12.00389.80% UpsideCurrent Analyst Ratings BreakdownCompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookABPAbpro$180K74.97N/AN/A($0.29) per share-0.77GTBPGT BiopharmaN/AN/AN/AN/A($0.75) per shareN/ALSBLakeShore Biopharma$80.82MN/AN/AN/A$8.86 per shareN/AMURAMural OncologyN/AN/AN/AN/A$8.22 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateABPAbpro-$7.23MN/A0.00∞N/AN/AN/A-198.95%N/AGTBPGT Biopharma-$13.16M-$5.69N/AN/AN/AN/A-1,033.08%-223.20%8/13/2025 (Estimated)LSBLakeShore Biopharma-$61.09MN/A0.00∞N/AN/AN/AN/A8/21/2025 (Estimated)MURAMural Oncology-$128.51M-$7.67N/AN/AN/AN/A-83.39%-70.70%8/12/2025 (Estimated)Latest GTBP, MURA, LSB, and ABP EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/13/2025Q2 2025GTBPGT Biopharma-$0.68N/AN/AN/AN/AN/A8/12/2025N/AMURAMural Oncology-$1.13N/AN/AN/AN/AN/A5/15/2025N/AABPAbproN/A-$0.08N/A-$0.08N/AN/A5/15/2025Q1 2025GTBPGT Biopharma-$0.64-$0.76-$0.12-$0.33N/AN/A5/14/2025Q1 2025MURAMural Oncology-$2.12-$1.93+$0.19-$1.93N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthABPAbproN/AN/AN/AN/AN/AGTBPGT BiopharmaN/AN/AN/AN/AN/ALSBLakeShore BiopharmaN/AN/AN/AN/AN/AMURAMural OncologyN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioABPAbproN/A0.110.11GTBPGT BiopharmaN/A0.730.73LSBLakeShore BiopharmaN/AN/AN/AMURAMural OncologyN/A5.085.08Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipABPAbpro23.30%GTBPGT Biopharma8.15%LSBLakeShore Biopharma52.64%MURAMural Oncology80.21%Insider OwnershipCompanyInsider OwnershipABPAbpro20.80%GTBPGT Biopharma3.40%LSBLakeShore BiopharmaN/AMURAMural Oncology2.20%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableABPAbpro1560.79 million48.14 millionN/AGTBPGT Biopharma83.27 million3.16 millionNo DataLSBLakeShore Biopharma773N/AN/AN/AMURAMural Oncology11917.27 million16.89 millionOptionableGTBP, MURA, LSB, and ABP HeadlinesRecent News About These CompaniesMinneapolis muralist honors Tuskegee airmenJuly 19 at 3:46 AM | msn.comMural Oncology, Inc.: Mural Oncology Announces Fourth Quarter and Year End 2024 Financial Results and Highlights Upcoming Clinical Milestones - FinanzNachrichten.deJuly 8, 2025 | finanznachrichten.deDemolition threatens breast cancer mural in 12 Points communityJuly 5, 2025 | wthitv.comWBuilding that features the PINK of Terre Haute wings mural to be demolishedJuly 4, 2025 | msn.com'Vibrancy': New murals proposed for Downtown Peoria parking decksJuly 3, 2025 | msn.comForm 8.3 - The Vanguard Group, Inc.: Mural Oncology plcJune 16, 2025 | markets.businessinsider.comBlackRock discloses 1.64% stake in Mural OncologyJune 13, 2025 | investing.comForm 8.3 - The Vanguard Group, Inc.: Mural Oncology plcJune 13, 2025 | markets.businessinsider.comBlackRock discloses 1.39% stake in Mural OncologyJune 12, 2025 | investing.comBlackRock Reveals 1.58% Holding in Mural OncologyJune 5, 2025 | msn.comCincinnati hospital honors late doctor with mural tributeMay 24, 2025 | local12.comLGoldman Sachs adjusts positions in Mural OncologyMay 21, 2025 | investing.comMural Oncology Announces Number of Relevant Securities in IssueMay 19, 2025 | globenewswire.comBlackRock discloses stake in Mural Oncology plcMay 15, 2025 | investing.comLongtime Lawrence artist Louis Copt, known for Kansas landscape paintings, diesMay 10, 2025 | www2.ljworld.comWBlackRock discloses stake in Mural OncologyMay 3, 2025 | investing.comGoldman Sachs discloses stake in Mural OncologyMay 3, 2025 | investing.comMural Oncology plc Opening Position Disclosure Under Irish Takeover RulesApril 30, 2025 | quiverquant.comQFORM 8.1(a) & (b) - Mural Oncology plcApril 30, 2025 | globenewswire.com‘Final mark on his legacy’: Wood County artists dedicate work to muralist who died in JanuaryApril 29, 2025 | msn.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeGTBP, MURA, LSB, and ABP Company DescriptionsAbpro NASDAQ:ABP$0.22 -0.01 (-2.29%) As of 04:00 PM EasternAbpro Holdings Inc. is a biotechnology company. The company's mission is to improve the lives of mankind facing severe and life-threatening diseases with next-generation antibody therapies. Abpro Holdings Inc., formerly known as Atlantic Coastal Acquisition Corp. II, is based in WOBURN, Mass.GT Biopharma NASDAQ:GTBP$1.99 -0.03 (-1.49%) Closing price 04:00 PM EasternExtended Trading$1.98 0.00 (-0.25%) As of 05:52 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.GT Biopharma, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology products based on its proprietary Tri-specific Killer Engager (TriKE) fusion protein immune cell engager technology platform. It develops GTB-3550, a single-chain tri-specific recombinant fusion protein conjugate that is in Phase I clinical trial for the treatment of myelodysplastic syndromes, refractory/relapsed acute myeloid leukemia or advanced systemic mastocytosis, and CD33+ malignancies. The company is developing GTB-3650, which is in preclinical studies that target CD33 on the surface of myeloid leukemias; and GTB-5550 that is in preclinical studies for treating patients with B7-H3 positive solid tumors. GT Biopharma, Inc. has a co-development partnership agreement with Altor BioScience Corporation for the clinical development of a 161533 (GTB-3550) TriKE fusion protein for cancer therapies; and a license agreement with the Regents of the University of Minnesota to develop and commercialize cancer therapies using TriKE technology. The company was formerly known as OXIS International, Inc. and changed its name to GT Biopharma, Inc. in July 2017. GT Biopharma, Inc. was incorporated in 1965 and is based in Brisbane, California.LakeShore Biopharma NASDAQ:LSB$1.19 +0.11 (+10.19%) Closing price 03:59 PM EasternExtended Trading$1.16 -0.02 (-2.10%) As of 05:54 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.LakeShore Biopharma Co., Ltd. engages in the provision of discovering, developing, manufacturing, and commercializing vaccines and therapeutic biologics for infectious diseases and cancer. It focuses on developing PIKA technology platform. It operates through the People's Republic of China and Other Countries or Regions. The company was founded by Yi Zhang on November 16, 2020 and is headquartered in Beijing, China.Mural Oncology NASDAQ:MURA$2.45 -0.03 (-1.21%) Closing price 04:00 PM EasternExtended Trading$2.50 +0.05 (+1.88%) As of 04:08 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Mural Oncology plc, a clinical-stage oncology company, focuses on discovering and developing immunotherapies for the treatment of patients with cancer. The company's lead product candidate includes nemvaleukin alfa for the treatment of mucosal melanoma as a monotherapy and platinum-resistant ovarian cancer in combination with pembrolizumab. It also develops nemvaleukin to treat cutaneous melanoma and advanced solid tumors. The company is also developing engineered interleukin-18 and tumor-targeted interleukin-12 programs. Mural Oncology plc was incorporated in 2017 and is based in Dublin, Ireland. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Block Levels Up: What S&P 500 Inclusion Means for Investors Steel Dynamics Stock Steady on Long-Term Prospects A Bullish Storm Is Brewing for High-Yield Verizon’s Share Price Forget the Hype—TSMC Is the AI Stock That Actually Delivers Rigetti Soars 30% on Latest Quantum Leap: What It Means Long-Term Domino’s Delivers Another Discounted Entry for Income Investors Palantir Bulls and Bears Set for an August Showdown 3 Reasons Palo Alto Networks Is Becoming a Wall Street Favorite Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.